Fintel reports that on November 14, 2024, Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (NasdaqCM:ADIL) with a ...

Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...

Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $8 price target The firm believes Adial has the potential to outperform over the next 12 months, saying its ...

Short interest in Adial Pharmaceuticals Inc (NASDAQ:ADIL) decreased during the last reporting period, falling from 77.82K to 51.17K. This put 0.82% of the company's publicly available shares short.

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...

SAIHEAT Limited (f/k/a SAI.TECH Global Corporation) ("SAIHEAT” or the "Company”) (NASDAQ: SAIH, SAITW) is pleased to unveil the SAIHEAT BASE PLAN 2029, an ambitious initiative delivering integrated ...

More than 40,000 Gen Z and millennial Bumble users worldwide, including over 2,000 singles in India, participated in the survey.